Trusted by leading UK researchers: Our retatrutide product is sourced exclusively from reputable and certified laboratories, trusted by leading academic and clinical institutions across the UK
This reduces the risk of hypoglycaemia compared to some other diabetes medications
Versus semaglutide (GLP-1 mono-agonist) : considerable gap
These include: Nausea (the most frequently reported adverse effect) Vomiting Diarrhoea Constipation Decreased appetite (which, while contributing to weight loss, can occasionally be excessive) These effects were generally mild to moderate in severity and occurred most frequently during the dose-escalation phase
A recent Survey of Ophthalmology review synthesized findings from cardiovascular outcomes trials, retrospective database analyses, meta-analyses and preclinical studies involving semaglutide, liraglutide, dulaglutide and related agents across six ocular conditions: diabetic retinopathy (DR), glaucoma, nonarteritic anterior ischemic optic neuropathy (NAION), age-related macular degeneration (AMD), idiopathic intracranial hypertension (IIH) and dry eye disease (DED)